DanCann Pharma A/S (NGM:DANCAN)
Sweden · Delayed Price · Currency is SEK · Price in DKK 1.020
+0.080 (8.51%)
At close: Aug 13, 2025
DanCann Pharma Company Description
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas.
It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients.
The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros.
It is also involved in the import and distribution of Bedrocan CannGros, Bedica CannGros, and Bediol CannGros.
The company was incorporated in 2018 and is based in Ansager, Denmark.
DanCann Pharma A/S
| Country | Denmark |
| Founded | 2018 |
| Industry | Pharmaceutical Preparations |
| Employees | 5 |
| CEO | Jeppe Rasmussen |
Contact Details
Address: RugvAenget 5 Ansager, 6823 Denmark | |
| Phone | 45 69 16 03 93 |
| Website | dancann.com |
Stock Details
| Ticker Symbol | DANCAN |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeppe Rasmussen | Chief Executive Officer |
| Peter Sondergaard | Chief Financial Officer |